Thyroid lymphoma is a rare cancer that starts in immune cells within the thyroid gland, rather than in the thyroid cells themselves. It accounts for about 5% of all thyroid cancers and roughly 2% of lymphomas that develop outside the lymph nodes, with an estimated 2 cases per million people each year. Unlike the more common types of thyroid cancer, thyroid lymphoma behaves like a lymphoma elsewhere in the body and is treated with similar approaches.
How Thyroid Lymphoma Differs From Other Thyroid Cancers
Most thyroid cancers, like papillary or follicular thyroid cancer, arise from the hormone-producing cells of the thyroid. Thyroid lymphoma is fundamentally different. It originates from white blood cells (specifically B cells) that have accumulated in the thyroid tissue. This distinction matters because it changes everything about how the disease is diagnosed, staged, and treated. Surgery, which is the primary approach for most thyroid cancers, plays a much smaller role here.
One important clinical challenge is telling thyroid lymphoma apart from anaplastic thyroid cancer, an aggressive thyroid malignancy that can look very similar on initial examination. Both can present as a rapidly growing neck mass. The key difference is found under the microscope: thyroid lymphoma cells carry markers typical of immune cells, while anaplastic thyroid cancer cells carry markers of epithelial (tissue-lining) cells. Getting this distinction right is critical because the treatments are completely different.
The Main Subtypes
Nearly all thyroid lymphomas are a type called non-Hodgkin lymphoma, and the vast majority are B-cell derived. The two most common subtypes are diffuse large B-cell lymphoma (DLBCL) and MALT lymphoma. DLBCL is the more aggressive form and accounts for over 50% of cases, with some estimates as high as 70%. MALT lymphoma, a slower-growing type, makes up roughly 10 to 23% of cases. A smaller number of patients have a mixed type that combines features of both.
The subtype has a major impact on how the disease behaves. MALT lymphoma tends to stay confined to the thyroid for longer and generally carries a better prognosis. DLBCL is more likely to spread beyond the thyroid and typically requires more intensive treatment.
The Strong Link to Hashimoto’s Thyroiditis
The single biggest risk factor for thyroid lymphoma is a pre-existing autoimmune thyroid condition called Hashimoto’s thyroiditis. Between 60 and 90% of patients diagnosed with thyroid lymphoma also have Hashimoto’s, and having it increases the risk of developing thyroid lymphoma by 67 to 80 times compared to the general population.
The connection makes biological sense. In Hashimoto’s thyroiditis, the immune system chronically attacks the thyroid, flooding it with lymphocytes (white blood cells) over years or decades. That prolonged immune stimulation creates an environment where those lymphocytes are more likely to undergo cancerous changes. This doesn’t mean that most people with Hashimoto’s will develop lymphoma. The absolute risk remains very low because thyroid lymphoma itself is so rare. But a new, rapidly growing mass in someone with a long history of Hashimoto’s should raise suspicion.
Symptoms and How It Presents
The hallmark symptom is a rapidly enlarging mass in the neck. Unlike many thyroid cancers that grow slowly over months or years, thyroid lymphoma, particularly the DLBCL subtype, can grow noticeably over days to weeks. This rapid expansion is often what prompts people to seek medical attention.
As the mass grows, it can compress surrounding structures in the neck. Common symptoms include difficulty swallowing from pressure on the esophagus, shortness of breath or noisy breathing from tracheal compression, and hoarseness from pressure on the nerve that controls the vocal cords. Around 10 to 12% of patients also experience what are called B symptoms: unexplained fevers, drenching night sweats, and unintentional weight loss. These systemic symptoms suggest the lymphoma may have spread beyond the thyroid.
Diagnosis and Staging
Ultrasound is typically the first imaging tool used and can reveal a few characteristic patterns: a single nodule, a diffusely enlarged gland, or a mix of both. From there, a tissue sample is essential. Fine needle aspiration, the standard biopsy method for thyroid nodules, can sometimes provide enough cells for diagnosis, particularly when combined with specialized lab techniques like flow cytometry and immunohistochemistry that identify the specific cell markers on the tumor. In many cases, though, a larger tissue sample from a core needle biopsy or a small surgical biopsy is needed to confirm the diagnosis and determine the subtype.
Once confirmed, the disease is staged using the Ann Arbor system, the same framework used for lymphomas throughout the body. Stage IE means the lymphoma is confined to the thyroid. Stage IIE means it has spread to nearby lymph nodes in the neck. Stage IIIE involves lymph node regions on both sides of the diaphragm or the spleen. Stage IVE describes widespread disease. PET scans can be useful for determining the full extent of the disease and later for assessing how well treatment is working. MRI may be more sensitive than CT for detecting whether the lymphoma has extended beyond the thyroid into surrounding tissues.
Treatment by Subtype and Stage
Treatment depends heavily on which subtype is present and how far it has spread.
For MALT lymphoma that remains localized to the thyroid, radiation therapy alone is often sufficient. This slower-growing subtype responds well to local treatment, and outcomes with radiation are excellent. In select cases, surgery alone has also been used for very localized MALT disease. Doses as low as 24 radiation treatments over about two and a half weeks can be effective for early-stage, slow-growing disease.
For DLBCL and other aggressive subtypes, the standard approach is chemotherapy followed by radiation to the thyroid area. The most commonly used chemotherapy regimen combines a targeted antibody with several traditional chemotherapy drugs, typically given over multiple cycles. Patients who achieve a complete response after at least three cycles of chemotherapy and then receive follow-up radiation have shown particularly durable results. Chemotherapy alone carries a higher risk of the lymphoma returning in or near the thyroid, which is why adding radiation to the treatment plan improves outcomes for higher-grade disease.
Surgery to remove the thyroid plays a limited role. It may be used for diagnosis or occasionally for a very early, localized case, but it is not the primary treatment strategy the way it is for papillary or follicular thyroid cancer.
Survival and Prognosis
Overall, the outlook for thyroid lymphoma is relatively favorable compared to many other lymphomas, with a median survival of 9.3 years across all stages and subtypes. Stage at diagnosis and subtype are the two strongest predictors of outcome.
Five-year disease-specific survival rates by stage are:
- Stage I: approximately 86%
- Stage II: approximately 81%
- Stage III/IV: approximately 64%
When broken down further by subtype, the differences become even more striking. MALT lymphoma diagnosed at stage I has a five-year survival rate of about 97.5%. DLBCL at stage I has an approximately 82% five-year survival rate. For both subtypes, advanced-stage disease carries significantly worse outcomes, dropping to around 50 to 60% at five years for stage III or IV.
Other factors associated with worse survival include older age at diagnosis and not receiving radiation as part of treatment. Patients with MALT lymphoma generally do best overall, reflecting its slower-growing nature and high sensitivity to treatment.